Alaunos Therapeutics Dividend
Dividend criteria checks 0/6
Alaunos Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$2.19 |
| Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?
Nov 10
Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology
Oct 04Alaunos posts 51% tumor reduction for lung cancer therapy
Sep 21Alaunos sheds 52% ahead of data readout for T-cell therapy platform
Sep 15Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data
Aug 31Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02
Aug 15Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?
Jul 26Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?
Apr 06Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?
Dec 20Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies
Jun 19ZIOPHARM records sharpest gain in nearly four months
Jun 09Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?
May 11ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?
Mar 09We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely
Jan 15ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022
Jan 14Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients
Dec 21Activist holder wins Ziopharm Oncology board seats
Dec 17Ziopharm Oncology CFO to step down
Dec 14What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?
Nov 23
Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution
Nov 20ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Ziopharm Oncology thumbs down on investor's call for board seats
Nov 02Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TCRT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TCRT's dividend payments have been increasing.
Dividend Yield vs Market
| Alaunos Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (TCRT) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (TCRT) | n/a |
Notable Dividend: Unable to evaluate TCRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TCRT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate TCRT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TCRT has not reported any payouts.